Dr. Benjamin Nadeau, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Arkansas College of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 629
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Arkansas College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license 48761 · GA license 68076
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Healthcare System, Inc Chattanooga, TN
- Erlanger Medical Center Chattanooga, TN
- Parkridge Medical Center Chattanooga, TN
Medical groups
- Tennessee Oncology PLLC (358 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 629
- Services billed
- 156,125
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 36,750 | 33 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 18,175 | 159 |
| Injection, pembrolizumab, 1 mg | 17,800 | 18 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 6,710 | 15 |
| Injection, denosumab, 1 mg | 4,020 | 18 |
| Injection, paclitaxel, 1 mg | 2,923 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,652 | 65 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,677 | 387 |
| Insertion of needle into vein for collection of blood sample | 1,391 | 377 |
| Blood test, comprehensive group of blood chemicals | 1,384 | 371 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Chattanooga, TN | 148 |
| Abiraterone Acetate | 116 |
| Ondansetron Hcl Other prescribers in Chattanooga, TN | 83 |
| Potassium Chloride Other prescribers in Chattanooga, TN | 77 |
| Prochlorperazine Maleate Other prescribers in Chattanooga, TN | 74 |
| Eliquis (apixaban) Other prescribers in Chattanooga, TN | 72 |
| Revlimid (lenalidomide) | 68 |
| Pantoprazole Sodium Other prescribers in Chattanooga, TN | 68 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Chattanooga, TN | 52 |
| Ondansetron Odt (ondansetron) Other prescribers in Chattanooga, TN | 46 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 32 companies reported 69 payments worth $1,762 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $268 |
|---|---|
| Novartis Pharmaceuticals Corporation | $105 |
| E.r. Squibb & Sons, L.l.c. | $104 |
| Astellas Pharma US Inc | $99.96 |
| Regeneron Healthcare Solutions, Inc. | $99.87 |
| Janssen Biotech, Inc. | $89.44 |
| Aveo Pharmaceuticals, Inc. | $86.62 |
| Taiho Oncology, Inc. | $72.75 |
| Food and Beverage | $1,694 |
|---|---|
| Education | $68.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.